Millions of COVID-19 Shots Ready for Children Under 5: White House
Children under 5 are the only age group in the United States not yet eligible for COVID-19 shots
COVID19 Vaccine
MPR Weekly Dose Podcast #119
The FDA Advisory Committee vote on Novavax; new option for MMR vaccination; Dupixent approval expanded; and we take a look at the latest data on COVID-19 treatments.
FDA Panel Votes in Favor of EUA for Novavax COVID-19 Vaccine
NVX-CoV2373 is engineered from the genetic sequence of SARS-CoV-2 using the Company’s recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein.
Lower Risk of COVID-19 in Infants With Vaccination During Pregnancy
Infants of vaccinated mothers had reduced risk of a positive test; risk was lower during delta versus omicron period
Vaccination Offers Partial Protection for Postacute Phase of COVID-19
Individuals with breakthrough infection have increased risk for death, postacute sequelae compared with contemporary controls
Antibody Levels After COVID-19 Vaccination Inversely Linked to Body Weight
Inverse correlation sustained for up to 6 months following 2 doses of BNT162b2 in small cohort of healthy young and middle-aged adults
Pfizer-BioNTech COVID-19 Vaccine Elicits Strong Immune Response in Kids Under 5 After Third Dose
The trial included 1678 children who received a third dose of the 3µg formulation at least 2 months after the second dose of a 2-dose series at a time when Omicron was the predominant variant.
MPR Weekly Dose Podcast Episode 116
The FDA decide to decline COVID-19 treatment; Booster doses authorized for children; A direct to consumer test to detect COVID-19, influenza, and RSV; And a wearable furosemide delivery system accepted for review.
Pfizer-BioNTech COVID-19 Vaccine Booster Dose Authorized for 5- to 11-Year-Olds
The Pfizer-BioNTech COVID-19 vaccine can be administered as a single booster dose to individuals 5 to 11 years of age at least 5 months after completion of the primary series.
Vaccine Effectiveness Modest for Children, Teens During Omicron
BNT162b2 vaccine effectiveness against symptomatic infection modest and declined rapidly, was higher after booster dose in teens
